In vivo Hybridoma Approach to Identify Novel Therapeutic- and Diagnostic-Grade Antibodies
The Curia hybridoma platform offers a variety of high-performance hybridoma technologies to discover great antibodies. The specific discovery approach depends on project-intrinsic parameters. These comprise practical (client resource, timeline) and scientific considerations. For the latter, we perform a rigorous upfront target analysis to devise the best discovery approach. Here we use bioinformatics, literature, and patent data to identify target-specific considerations that could impact our discovery efforts. This due diligence helps ensure that we are following an optimal path for antibody discovery from the outset.
View our latest hydrodynamic gene transfer (HDT) publications related to DNA-based immunization: